Paige gets nod in Europe for prostate biomarker suite

By LabPulse.com staff writers

May 12, 2022 -- Artificial intelligence (AI) developer Paige has received CE-in vitro diagnostic and U.K. Conformity Assessed marks for its Paige Prostate Biomarker Suite.

The AI software is designed to detect the presence of four prostate cancer biomarkers on digitized tissue images stained with hematoxylin and eosin (H&E).

This is the first European regulatory certification of image-based biomarker detection on H&E-stained tissue samples for Paige, and will potentially expand the utility of AI to analyze tissues prepared with the most frequently used stain in histology, the company said in a release.

Paige names additions to scientific advisory board
Artificial intelligence (AI) company Paige made recent appointments to its scientific advisory board. The new additions include leaders in pathology,...
Ultivue, Paige partner to advance AI products
Boston-based biomarker assay developer Ultivue and artificial intelligence (AI) software developer Paige have established a collaborative agreement to...
Paige receives marks for breast lymph node AI software
Artificial intelligence (AI) developer Paige recently received CE-in vitro diagnostic and U.K. Conformity Assessed marks for its Paige Breast Lymph Node.
Paige unveils breast lymph node software at USCAP 2022
Artificial intelligence-based software developer Paige unveiled its breast lymph node application at this week's United States and Canadian Academy of...
Paige links with Flagship on biomarker analysis tools
Pathology artificial intelligence software developer Paige has inked a partnership with Flagship Biosciences that makes Flagship's diagnostics software...

Copyright © 2022 LabPulse.com

Last Updated mp 5/12/2022 1:38:52 PM